Leqvio® advances toward broader access with agreement between Novartis and the pan-Canadian Pharmaceutical Alliance
— Eligible Canadian patients with heterozygous familial hypercholesterolemia (HeFH) are one step closer to publicly funded access to cholesterol lowering treatment. Novartis Pharmaceuticals Canada Inc. is pleased to announce the successful conclusion of negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for the public reimbursement of Leqvio® (inclisiran) for the treatment of adults with heterozygous familial […]